Neurocrine Biosciences
NBIX
$114.66
Share price
0.86%
Change (1 day)
21.90%
Change (1 year)
Categories
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.
EPS for Neurocrine Biosciences (NBIX)
EPS in 2023 (TTM): $1.83
According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $1.83. In 2022 the company made an earnings per share (EPS) of $1.61 an increase over its 2021 EPS that were of $0.95.
EPS history for Neurocrine Biosciences from 2001 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | $1.83 | 13.66% |
| 2022 | $1.61 | 69.47% |
| 2021 | $0.95 | -78.21% |
| 2020 | $4.36 | 990% |
| 2019 | $0.40 | 81.82% |
| 2018 | $0.22 | -113.5% |
| 2017 | -$1.63 | 0.62% |
| 2016 | -$1.62 | 57.28% |
| 2015 | -$1.03 | 25.61% |
| 2014 | -$0.82 | 18.84% |
| 2013 | -$0.69 | -1085.71% |
| 2012 | $0.07000 | -89.71% |
| 2011 | $0.68 | -500% |
| 2010 | -$0.17 | -86.92% |
| 2009 | -$1.30 | -43.48% |
| 2008 | -$2.30 | -57.8% |
| 2007 | -$5.45 | 92.58% |
| 2006 | -$2.83 | 371.67% |
| 2005 | -$0.60 | -52.76% |
| 2004 | -$1.27 | 36.56% |
| 2003 | -$0.93 | -70% |
| 2002 | -$3.10 | 118.31% |
| 2001 | -$1.42 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $3.82 | 108.74% | 🇺🇸 USA |
 AbbVie ABBV | $4.89 | 167.09% | 🇺🇸 USA |
 Eli Lilly LLY | $7.10 | 287.94% | 🇺🇸 USA |
 Repligen
RGEN | $2.49 | 36.07% | 🇺🇸 USA |
 Athersys ATHX | -$3.03 | -265.57% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | -$0.47 | -125.68% | 🇺🇸 USA |
 Palatin Technologies PTN | -$2.96 | -261.75% | 🇺🇸 USA |
 Royalty Pharma RPRX | $0.55 | -69.95% | 🇬🇧 UK |